(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. The company has said previously it expects sales from the drug to eventually reach $1 billion a year. It said in a statement […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Pittsburgh, Penn.-based Mylan Inc. (MYL)’s $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) has been rejected by the company, after Perrigo said late Tuesday that the offer “substantially undervalues” Perrigo and “its future growth prospects and “is not in the best interests of Perrigo’s shareholders.” “Perrigo has a long history of driving above […]
Biogen has three women on its 10-member board of directors, an unusual feat in corporate America and the biotech industry. But instead of patting itself on the back with a round of attaboys and attagirls, the Cambridge powerhouse wanted to do more: help other companies put women on their boards. Where to find talented women? […]
Thousand Oaks, Calif.-based Amgen (AMGN) announced stellar first quarter revenues yesterday, deflecting a failed asthma clinical trial. The company announced a total revenue increase of 11 percent for the first quarter of 2015 compared to the same period last year, rising from $4.521 billion to $5.033 billion. Revenues were driven by sales of Enrel, Prolia, […]
– FIRST-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH– FIRST-QUARTER ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.47, ABOVE PREVIOUS GUIDANCE RANGE AND REFLECTING 38 PERCENT GROWTH; GAAP EPS FROM CONTINUING OPERATIONS OF $0.35– FULL-YEAR 2015 EPS GUIDANCE RANGE FOR CONTINUING OPERATIONS REMAINS UNCHANGED– COMPLETES THE SALE OF ITS DEVELOPED MARKETS BRANDED GENERICS PHARMACEUTICALS BUSINESS ABBOTT PARK, Ill., April […]
RICHMOND, Calif., April 22, 2015 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its first quarter 2015 financial results and accomplishments. For the first quarter ended March 31, 2015, Sangamo reported a consolidated net loss of $5.3 million, or $0.08 per share, compared to a net loss of $7.6 million, or $0.12 per share, for […]
In the red hot market for pharmaceutical deal-making it’s either eat or be eaten. That’s the case with Teva Pharmaceutical’s $82 a share cash and stock bid for generic competitor Mylan, a direct challenge to Mylan’s near $30 billion takeover bid for Perrigo, unveiled on April 8. The question now is whether Mylan’s board of […]
Lenexa, KS (April 21, 2015) – Contract Research Organization XenoTech, LLC, a division of Sekisui, has announced plans to relocate into a new 41,500 ft2 facility. The planned move will double the size of XenoTech’s global headquarters, currently located at 16825 W. 116th St. in Lenexa, KS. The new facility, boasting nearly two and a […]
EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors
HEMEL HEMPSTEAD, England, April 21, 2015 /PRNewswire/ — EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göran Ando as a Non-Executive Director. Bryan Morton, who established EUSA Pharma as founder and first CEO, will become Executive Chairman. […]
DUBLIN, April 21, 2015 /PRNewswire/ — Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE) today announced that its Board of Directors has unanimously rejected the unsolicited Proposal (the “Proposal”) from Mylan NV (“Mylan”) (NASDAQ: MYL), disclosed April 8, 2015, to acquire all of the outstanding shares of Perrigo for $205.00 per share. Following a thorough review, advised […]